MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System
News provided by
Share this article
Share this article
NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the execution of a Memorandum of Understanding (the "MOU") regarding the launch of an exclusive collaborative development program to optimize the delivery of certain psychedelic drug candidates, leveraging Nextage's proprietary Brain Targeting Liposome System (BTLS) delivery technology, for which it has an exclusive license.  MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

Related Keywords

Germany ,Canada ,Israel ,Israeli ,Canadian ,Abraham Dreazen ,Miri Halperin Wernli ,Exchange Commission ,Nasdaq ,Medicine Mindmed Inc ,Nextar Chempharma Solutions ,Pilot Program ,Teva Pharmaceuticals ,Nextage Therapeutics ,Brain Targeting Liposome System ,Blood Brain ,Med Executive President ,Blood Brain Barrier ,Israel Makov ,Mind Medicine Mindmed Inc ,ஜெர்மனி ,கனடா ,இஸ்ரேல் ,இஸ்ரேலி ,கனடியன் ,மீறி ஹால்பெரின் வெற்ணிலி ,பரிமாற்றம் தரகு ,நாஸ்டாக் ,பைலட் ப்ரோக்ர்யாம் ,தேவா மருந்துகள் ,அடுத்தது சிகிச்சை ,இரத்தம் மூளை ,மேட் நிர்வாகி ப்ரெஸிடெஂட் ,இரத்தம் மூளை தடை ,